Takeda Pharmaceutical Co (STU:TKD) Cyclically Adjusted Book per Share: €27.73 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TKD Takeda Pharmaceutical Co Ltd STU:TKD
73 GF Score
Price €32.48
GF Value €24.72
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Cyclically Adjusted Book per Share?

Takeda Pharmaceutical Co STU:TKD 73 Cyclically Adjusted Book per Share is €27.73 as of Jun. 2026. GuruFocus rates STU:TKD with a GF Score™ of 73/100 and a GF Value™ of €24.72 (Significantly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted book value per share for the three months ended in Jun. 2026 was €25.742. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €27.73 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Takeda Pharmaceutical Co's average Cyclically Adjusted Book Growth Rate was 6.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 6.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Takeda Pharmaceutical Co was 7.10% per year. The lowest was 1.30% per year. And the median was 4.00% per year.

As of today (2026-09-17), Takeda Pharmaceutical Co's current stock price is €32.48. Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €27.73. Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio of today is 1.17.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Takeda Pharmaceutical Co was 2.42. The lowest was 1.03. And the median was 1.34.


Takeda Pharmaceutical Co  (STU:TKD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=32.48/27.734
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Takeda Pharmaceutical Co was 2.42. The lowest was 1.03. And the median was 1.34.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Takeda Pharmaceutical Co Cyclically Adjusted Book per Share Related Terms


Takeda Pharmaceutical Co Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Cyclically Adjusted Book per Share Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.12 25.01 25.98 27.18 27.83

Takeda Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.06 27.20 27.49 27.48 27.73

STU:TKD vs ZTS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio falls into.


STU:TKD
73GF Score
Takeda Pharmaceutical Co Ltd STU:TKD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takeda Pharmaceutical Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=25.742/113.6000*113.6000
=25.742

Current CPI (Jun. 2026) = 113.6000.

Takeda Pharmaceutical Co Quarterly Data

Book Value per Share CPI Adj_Book
201609 21.150 98.000 24.517
201612 21.286 98.400 24.574
201703 20.943 98.100 24.252
201706 20.355 98.500 23.475
201709 20.259 98.800 23.294
201712 20.196 99.400 23.081
201803 19.742 99.200 22.608
201806 20.374 99.200 23.332
201809 20.988 99.900 23.866
201812 20.760 99.700 23.654
201903 26.838 99.700 30.580
201906 25.490 99.800 29.015
201909 26.532 100.100 30.110
201912 25.661 100.500 29.006
202003 25.620 100.300 29.017
202006 24.766 99.900 28.162
202009 24.141 99.900 27.452
202012 23.492 99.300 26.875
202103 25.499 99.900 28.996
202106 25.372 99.500 28.967
202109 26.179 100.100 29.710
202112 26.141 100.100 29.667
202203 27.145 101.100 30.501
202206 28.769 101.800 32.104
202209 30.456 103.100 33.558
202212 28.215 104.100 30.790
202303 28.271 104.400 30.762
202306 28.236 105.200 30.491
202309 28.527 106.200 30.515
202312 27.596 106.800 29.353
202403 28.363 107.200 30.056
202406 28.828 108.200 30.267
202409 27.352 108.900 28.532
202412 28.760 110.700 29.513
202503 27.286 111.100 27.900
202506 25.925 111.700 26.366
202509 26.018 112.000 26.390
202512 26.288 113.000 26.428
202603 25.659 112.700 25.864
202606 25.742 113.600 25.742

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €27.73 mean?
Takeda Pharmaceutical Co (STU:TKD) has a Cyclically Adjusted Book per Share of €27.73 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share too high?
Takeda Pharmaceutical Co's current Cyclically Adjusted Book per Share is €27.73. Overall, Takeda Pharmaceutical Co has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share compare to ZTS?
Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share of €27.73 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Cyclically Adjusted Book per Share is €27.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (STU:TKD) is currently considered Significantly Overvalued. The stock's GF Value™ is €24.72, compared to a current price of €32.48 — trading 31.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is €27.73. Takeda Pharmaceutical Co's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Takeda Pharmaceutical Co (STU:TKD), the current Cyclically Adjusted Book per Share is €27.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (STU:TKD) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of €32.48 is trading 31.4% above its estimated GF Value™ of €24.72. GuruFocus considers Takeda Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for STU:TKD:

  • Cyclically Adjusted Book per Share: €27.73
  • GF Value™: €24.72 vs. price of €32.48 (31.4% above fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the STU:TKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
73GF Score

Get the complete analysis for STU:TKD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.48
Price
€24.72
GF Value